Canada · Delayed Price · Currency is CAD Algernon Health Company Description
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia.
The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program.
It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries.
The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025.
Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christopher Moreau |
Contact Details
Address: 601 West Broadway Vancouver, British Columbia V5Z 4C2 Canada | |
| Phone | 604 398 4175 |
| Website | algernonhealth.com |
Stock Details
| Ticker Symbol | AGN |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | September - August |
| Reporting Currency | CAD |
| ISIN Number | CA01559R4008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Moreau | Chief Executive Officer |
| James Kinley | Chief Financial Officer |
| Christopher Bryan | Chief Operating Officer |